Table 4.
Clinical studies investigating the use of bioactive glass S53P4 in patients with chronic osteomyelitis; reviews and animal and in vitro studies are not included.
| Author | Year | No. of | Bone | Persistent or | Comment |
|---|---|---|---|---|---|
| patients | substitute | reinfection | |||
| Lindfors | 2017 | 116 | BAG | 12 (10.3 %) | No control group |
| Lindfors | 2010 | 11 | BAG | 1 (9.1 %) | No control group |
| Drago | 2013 | 27 | BAG | 3 (11.1 %) | No control group |
| McAndrew | 2013 | 3 | BAG | 0 (0 %) | No control group |
| Romano | 2014 | 76 | BAG ( 27) vs. antibiotic-loaded HA and calcium sulfate ( 27) vs. antibiotic-loaded demineralized bone matrix and tricalcium phosphate ( 22) | 2 (7.4 %) 3 (11.1 %) 3 (13.6 %) | No significant differences |
| Ferrando | 2017 | 25 | BAG ( 12) vs. calcium sulfate antibioticbeads ( 13) | 1 (8.3 %) 1 (7.7 %) | No significant differences |
| Malat | 2018 | 50 | BAG | 7 (14 %) | No control group |
| Oosthuysen | 2019 | 24 | BAG | 2 (8 %) | No control group |
HA: hydroxyapatite; BAG: bioactive glass.